Las Vegas 2024
09/06/2024 - 09/08/2024
8:00 am - 1:00 pm
Where: Horseshoe Resort and Casino
Topics include: diabetes, dermatological disorders, hypertension & Dyslipidemia
Las Vegas 2024
HOTEL INFO: Please call us to assist with room reservation
Horseshoe Las Vegas Resort & Casino (formerly Bally’s)
Group rate $55 Thursday night, $146 Friday night and $210 Saturday nights single or double occupancy. Extra adult in room $30 per night. Max of 4 people in room.
www.ballyslasvegas.com
Friday September 6, 2024
Dr. Joshua Neumiller, Pharm D., CDE, CGP, FASCP
Washington State University
Joshua Neumiller received his doctor of pharmacy degree from Washington State University in 2005, where he is currently an assistant professor in the Department of Pharmacotherapy and a member of WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller is a Certified Diabetes Educator (CDE), a Certified Geriatric Pharmacist (CGP), and is a Fellow of the American Society of Consultant Pharmacists. Dr. Neumiller has published on a variety of practice and research-based topics, and is a contributing author for the ADA journal Diabetes Spectrum, and is the lead pharmacist CE reviewer for the American Association of Diabetes Educators. Clinically, Dr. Neumiller is a consultant pharmacist at Elder Services, a division of Spokane Mental Health, where he provides in-home consulting services. He also serves as an investigator on multiple investigator-initiated and large multi-site clinical trials involving the study of diabetes and its complications.
UPDATE ON THE MANAGEMENT OF TYPE 2 DIABETES AND RELATED COMORBIDITIES
ACPE# 0088-9999-24-058-L01-P
Objectives:
1. Review current glycemic goals and targets for patients with type 2 diabetes.
2. Discuss recommended approaches to intensification of glucose-lowering therapies based on comorbidities and patient-specific considerations.
3. Review the impact of comorbid cardiovascular disease, heart failure, and/or chronic kidney disease on treatment selection.
4. Describe common side effects associated with glucose-lowering therapies and strategies to mitigate treatment risks.
5. Apply current treatment recommendations to a patient scenario to optimize patient outcomes
—————————————————————————————————————————————————————————————————–
Dr. Megan Willson, Pharm D.
Washington State University
Megan Willson is a Clinical Assistant Professor in the Pharmacotherapy Department of Washington State University College of Pharmacy. Megan enjoys lecturing on cardiovascular topics as well as patient simulation scenarios in patient care laboratories. She also serves as preceptor to acute care fourth year pharmacy students in the area of internal medicine.
Saturday September 7, 2024
DERMATOLOGICAL DISORDERS
ACPE # 0088-9999-24-059-L01-p
Objectives:
1. Explain pathophysiology of common skin conditions including immunologic and drug induced conditions.
2. Perform patient assessments including focused history and physical examination to differentiate between and assess severity of drug reactions, acne, psoriasis, atopic dermatitis, and cellulitis.
3. Recommend and compare therapy recommendations for each of the above dermatological conditions.
4. Discuss adverse effects, safety, and use of biologic agents for the treatment of psoriasis
—————————————————————————————————————————————————————————————————————————————–
Sunday September 8, 2024
HYPERTENSION & DYSLIPIDEMIA
ACPE # 0088-9999-24-060-L01-P
Objectives:
1. Discuss hypertension based on equations and apply how medications reduce blood pressure.
2. List primary and secondary forms of hypertension.
3. Determine blood pressure goals and appropriate drug therapy recommendations consistent with Hypertension guidelines in patients.
4. Define MOA of each drug class and explain how it relates to HR, SV, CO and SVR.
5. Recommend appropriate lifestyle modifications and medication regimens based on individual’s history, concomitant disease, physical exam, and current medications.
6. Discuss adverse effects and counseling points for each medication class.
7. Review the medications for the treatment of dyslipidemia including class, mechanisms of action, contraindications, benefits, clinical pearls, and adverse effect profiles.
8. Identify risk factors for dyslipidemia including lifestyle and drug-induced.
9. Assess and identify treatment strategies for myalgias associated with statin therapy.
10. Differentiate between statin intensity.
11. Based on ASCVD score, recommend appropriate statin intensity therapy.
12. Develop a therapeutic plan for the treatment of dyslipidemia including statins, PCKS-9 inhibitors, and ezetimibe.